Interleukin-2 in cancer therapy: Uses and optimum management of adverse effects

BioDrugs

Volumn 14, Issue 5, 2000, Pages 299-318

  Mekhail, Tarek ^a   Wood, Laura ^a   Bukowski, Ronald ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CARMUSTINE; CISPLATIN; CORTICOSTEROID; DACARBAZINE; FLUOROURACIL; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR; LISOFYLLINE; NITRIC OXIDE; RECOMBINANT INTERLEUKIN 2; TAURINE; TUMOR NECROSIS FACTOR RECEPTOR; VINBLASTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; AUTOIMMUNE DISEASE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; KIDNEY CARCINOMA; LUNG TOXICITY; MAJOR CLINICAL STUDY; MELANOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHODGKIN LYMPHOMA; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SKIN TOXICITY; STEM CELL TRANSPLANTATION;

EID: 0033661846     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014050-00003     Document Type: Review

References (144)

1. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
2. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or highdose interleukin-2 alone
3. Use of tumor-infilterating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: A preliminary report
4. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
5. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen
6. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
7. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high dose recombinant interleukin-2 therapy
8. High dose aldesleukin in renal cell carcinoma: Long term survival update
9. Natural history and therapy of metastatic renal cell carcinoma: Role of interleukin 2
10. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma
11. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic RCC: An interim report
12. Treatment of 283 consecutive patients with metastatic melanoma or renal cell carcinoma using high-dose bolus interleukin-2
13. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
14. Immunotherapy for RCC: The era of interleukin-2 based treatment
15. Phase II trial of high-dose intermittent interleukin-2 in metastatic RCC: A Southwest Oncology Group study
16. High dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma
17. Patients with metastatic RCC candidate for immunotherapy with cytokines, analysis of a single institution study on 181 patients
18. A comparison of 2 modes of administration of recombinant interleukin-2: Continuous intravenous infusion alone versus subcutaneous administration plus inteferon alfa in patients with advanced RCC
19. A phase II trial of continuous infusion recombinant interleukin-2 in patients with advanced RCC: A Southwest Oncology Group study
20. Traitment du cancer du rein metastatique avec un nouveau schema d'interleukine-2: Experience de l'institut Gustav-Roussy
21. Phase II study of continuous intravenous infusion of recombinant interleukin-2 in patients with advanced RCC
22. High-dose interleukin-2 two days a week for metastatic RCC: A FNCLCC multicenter study
23. Recombinant interleukin-2 in metastatic RCC: A European multicenter phase II study
24. Randomized study of interleukin-2 (IL-2) alone vs IL-2 plus lymphokine-activated killer cells for treatment of melanoma and renal cell cancer
25. Treatment of metastatic RCC by intermittent continuous intravenous infusion of recombinant interleukin-2: A single center phase II study
26. Metastatic renal cell carcinoma treated with low-dose interleukin-2: A phase II multicenter study
27. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced RCC
28. Randomized human interleukin-2, recombinant alfa-2a, or both in metastatic renal cell carcinoma
29. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha
30. Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha
31. Prognostic factors of the clinical response of subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic RCC
32. Interleukin-2 based hormone therapy for metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
33. A progress report on the outpatient treatment of patients with advanced renal cell carcinoma using subcutaneous recombinant interleukin-2
34. Effects of subcutaneous recombinant IL-2 on humoral immunity in advanced cancer patients
35. Subcutaneous IL-2 in advanced melanoma and kidney carcinoma
36. Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma
37. Antitumor effects of interleukin-2 against RCC: Basic study and clinical application
38. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer
39. The impact of interleukin-2 on survival in renal cancer: A multivariate analysis
40. Pharmacokinetics of recombinant human interleukin-2 in advanced renal cell carcinoma patients following subcutaneous application
41. Concomitant administration of recombinant human interleukin-2 and recombinant human interferon-alpha 2A: An active outpatient regimen in metastatic renal cell carcinoma
42. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: An outpatient multicenter trial
43. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced RCC
44. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update
45. Keynote address: Perspectives on the use of interleukin-2 in cancer treatment
46. Aggressive chemotherapy for melanoma
47. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma
48. Effective combination chemo/hormonal therapy for malignant melanoma: Experience with three consecutive trials
49. Chemotherapy for stage 4 melanoma: A three year experience with cisplatin, DTIC, BCNU, and tamoxifen
50. Sequential chemo-immunotherapy in the treatment of metastatic melanoma
51. Combination of chemotherapy with interleukin-2 and interferon alpha for the treatment of metastatic melanoma
52. Development and results of Biochemotherapy in metastatic melanoma: The University of Texas M.D. Anderson Cancer Center Experience
53. Development of biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
54. Cytotoxicity of interleukin-2-activated lymphocytes for leukemia and lymphoma cells
55. In vitro and in vivo susceptibility of human leukemic cells to lympkokine activated killer activity
56. Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: A pilot study
57. High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse
58. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the children's Cancer Group
59. Children's Cancer Group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia
60. Close simulation of acute graft-versus host disease by interleukin-2 administered after autologous bone marrow transplantation for hematological malignancy
61. Interleukin-2 after autologous stem cell transplantation for hematological malignancy: A phase I/II study
62. Interleukin-2-activated autologous bone marrow and peripheral blood stem cells in the treatment of acute leukemia and lymphoma
63. Prognostic factors in the treatment of human innunodeficiency virus associated nohodgkin's lymphoma: Analysis of AIDS clinical trials group protocol 142-low dose versus standard-dose m-BACOD plus granulocyte macrophage colony-stimulating factor: National Institute of Allergy and Infectious Diseases
64. The Th1-Th2 hypothesis of HIV infection: New insights
65. Low-dose interleukin-2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in SCID/SCID mice reconstituted with EBV-seropositive human peripheral blood lymphocytes
66. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity
67. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2
68. In vivo enhancement of antitumor immunity by interleukin 2-rich lymphokines
69. Modulation of specific active immunization against murine melanoma using recombinant cytokines
70. Characterization of the pulmonary lesions induced in rats by human recombinant interleukin-2
71. Interleukin-2 treatment causes acute loss of DC precursors and mature DC which rebound with the increase in lymphocytes
72. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine
73. Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis
74. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism of the febrile response to interleukin-2 in cancer patients
75. Cardiorespiratory effects of immunotherapy with interleukin-2
76. Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines
77. Effects of interleukin-2 on oxygen consumption in patients with advanced malignancy
78. Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock
79. The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells
80. Toxicity of immunotherapy and lymphokine-activated killer cells
81. The coronary circulation in human septic shock
82. Pathogenetic mechanisms of septic shock
83. Negative inotropic effects of cytokines on the heart mediated by nitrous oxide
84. Idiopathic giant cell myocarditis after autologous hematopoietic stem cell transplantation and interleukin-2 immunotherapy: A case report
85. Renal, volume, hormonal changes during therapeutic administration of recombinant interleukin-2 in man
86. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer
87. Effects of interleukin-2 on renal function in patients receiving immunotherapy for advanced cancer
88. Repetitive weekly cycles of interleukin-2: Clinical and immunologic effects of dose, schedule, and addition of indomethacin
89. Colonic perforation: An unusual complication of therapy with high-dose inteleukin-2
90. The hematologic toxicity of interleukin-2 in patients with metastatic melanoma and renal cell carcinoma
91. Transient focal neurologic deficits complicating interleukin-2 therapy
92. Interleukin-2 with and without LAK cells in metastatic renal cell carcinoma: The Lyon first-year experience in 20 patients
93. Brachial plexopathy associated associated with interleukin-2 therapy
94. Bilateral carpal tunnel syndrome associated with interleukin-2 therapy
95. Multifocal neurotoxicity during interleukin-2 therapy for malignant melanoma
96. Acute fatal leukoencephalopathy after interleukin-2 therapy
97. Multiple cerebral lesions complicating therapy with interleukin-2
98. An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy
99. IL-2-based immunotherapy alters circulating neutrophil Fc receptor expression and chemotaxic
100. Recombinant human tumor necrosis factor-alpha: Regulation of N-formylmethionylleucylphenylalanine receptor affinity and function in human neutrophils
101. Pathological findings associated with interleukin-2 based immunotherapy for cancer: A postmortem study of 19 patients
102. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy
103. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells
104. Chronic inflammatory arthritis after treatment with high-dose interleukin-2 for malignancy
105. Erythema nodosum in a patient with renal cell carcinoma treated with interleukin-2 and lymphokine-activated killer cells
106. Myositis associated with interleukin-2 therapy in a patient with metastatic renal carcinoma
107. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell carcinoma
108. Interleukin-2 and psoriasis
109. A case of fatal pemphigus vulgaris in association with beta interferon and interleukin-2 therapy
110. A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma
111. Combination biologic therapy with interleukin-2 and interferon-alpha in the outpatient treatment of metastatic renal cell carcinoma
112. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma
113. Interleukin-2 in combination with interferon-alpha and 5-flurouracil for metastatic renal cell carcinoma
114. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
115. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with flurouracil in patients with metastatic renal cell carcinoma: Results of a sequential nonrandomized Phase II study
116. Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells
117. In vivo administration of purified human interleukin-2: Half life, immunologic effects and expansion of peripheral lymphoid cells in vivo with recombinant IL-2
118. IL-6/IFN-beta-2 as a circulating hormone: Induction by cytokine administration in humans
119. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin-1
120. Interleukin-1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclo-oxygenase inhibition
121. Recombinant tumor necrosis factor increases pulmonary vascular permeability independent of neutrphils
122. Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer
123. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effects of endotoxin
124. A control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance
125. Dexamethazone inhibition of interleukin-1 beta production by human monocytes: Posttranslational mechanisms
126. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethazone: Prevention of an acquired neutophil chemotaxis defect and differential suppression of interleukin-2-associated side effects
127. Nosocomial sepsis associated with interleukin-2
128. Human cytokine receptors
129. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins
130. A Phase I clinical trial of interleukin-2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera receptor IgG chimera (TNFR: Fc)
131. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma
132. Mechanism of cultured endothelial injury induced by lymphokine-activated killer cells
133. IL-2 rapidly induces natural killer cell adhesion to human endothelial cells
134. An ultrastructural study of in-vivo interactions between lymphocytes and endothelial cells in the pathogenesis of the vascular leak syndrome induced by interleukin-2
135. Taurine attenuates recombiant interleukin-2-activated, lymphocyte-mediated endothelial cell injury
136. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin-2 therapy in advanced renal cancer and malignant melanoma
137. Il-2 stimulates the production of IL-1 α and IL-1 β by human peripheral blood mononuclear cells
138. Pro-interleukin-1 β production by a subpopulation of human T cells, but not NK cells, in response to interleukin-2
139. A two part Phase I trial of high-dose interleukin-2 in combination with soluble (Chinese hamster ovary) interleukin-1 receptor
140. Overproduction of nitric oxide in cytokine-mediated hypotension and septic shock
141. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin
142. Strategies to reduce side effects of Interleukin-2: Evaluation of the antihypotensive agent NG-monomethyl-L-arginine